Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer

NCT00661609 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00661609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00661609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
December 31, 2009
Enrollment
54 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, renal pelvis cancer, transitional cell bladder cancer, ureter cancer, urethra cancer